AASLD guidelines for the treatment of hepatocellular carcinoma

doi:10.1002/hep.29086

Practice Guideline

. 2018 Jan;67(1):358-380.

doi: 10.1002/hep.29086.

AASLD guidelines for the treatment of hepatocellular carcinoma

Julie K Heimbach¹, Laura M Kulik², Richard S Finn³, Claude B Sirlin⁴, Michael M Abecassis⁵, Lewis R Roberts⁶, Andrew X Zhu⁷, M Hassan Murad⁸, Jorge A Marrero⁹

Affiliations

¹ Division of Transplant Surgery, William J. von Liebig Transplant Center, Mayo Clinic, Rochester, MN.
² Department of Medicine, Division of Gastroenterology and Hepatology, Northwestern University, Chicago, IL.
³ Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine at the University of California, Los Angeles, Santa Monica Geffen School of Medicine at UCLA, Los Angeles, California.
⁴ Liver Imaging Group, Department of Radiology, University of California, San Diego.
⁵ Northwestern University Feinberg School of Medicine, Chicago, IL.
⁶ Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.
⁷ Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
⁸ Mayo Clinic Evidence-based Practice Center, Mayo Clinic, Rochester, MN.
⁹ Digestive and Liver Diseases Division, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX.

PMID: 28130846
DOI: 10.1002/hep.29086

Practice Guideline

AASLD guidelines for the treatment of hepatocellular carcinoma

Julie K Heimbach et al. Hepatology. 2018 Jan.

. 2018 Jan;67(1):358-380.

doi: 10.1002/hep.29086.

Authors

Julie K Heimbach¹, Laura M Kulik², Richard S Finn³, Claude B Sirlin⁴, Michael M Abecassis⁵, Lewis R Roberts⁶, Andrew X Zhu⁷, M Hassan Murad⁸, Jorge A Marrero⁹

Affiliations

¹ Division of Transplant Surgery, William J. von Liebig Transplant Center, Mayo Clinic, Rochester, MN.
² Department of Medicine, Division of Gastroenterology and Hepatology, Northwestern University, Chicago, IL.
³ Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine at the University of California, Los Angeles, Santa Monica Geffen School of Medicine at UCLA, Los Angeles, California.
⁴ Liver Imaging Group, Department of Radiology, University of California, San Diego.
⁵ Northwestern University Feinberg School of Medicine, Chicago, IL.
⁶ Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.
⁷ Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
⁸ Mayo Clinic Evidence-based Practice Center, Mayo Clinic, Rochester, MN.
⁹ Digestive and Liver Diseases Division, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX.

PMID: 28130846
DOI: 10.1002/hep.29086

No abstract available

PubMed Disclaimer

Cited by

Metastasis-directed ablation of hepatocellular carcinoma with pulmonary oligometastases: a long-term multicenter study.
Zhou Q, Li R, Wu S, Zhang Y, Wang W, Zhu K, Wang M, Huang Z, Duan F. Zhou Q, et al. Radiol Med. 2024 Nov 12. doi: 10.1007/s11547-024-01907-7. Online ahead of print. Radiol Med. 2024. PMID: 39531158
Single-cell and bulk transcriptomic datasets enable the development of prognostic models based on dynamic changes in the tumor immune microenvironment in patients with hepatocellular carcinoma and portal vein tumor thrombus.
Tong W, Zhong J, Yang Q, Lin H, Chen B, Lu T, Chen J, Luo N. Tong W, et al. Front Immunol. 2024 Oct 28;15:1414121. doi: 10.3389/fimmu.2024.1414121. eCollection 2024. Front Immunol. 2024. PMID: 39530087 Free PMC article.
Determining the gross tumor volume for hepatocellular carcinoma radiotherapy based on multi-phase contrast-enhanced magnetic resonance imaging.
Meng K, Gong G, Liu R, Du S, Wang R, Yin Y. Meng K, et al. Clin Transl Radiat Oncol. 2024 Oct 22;50:100877. doi: 10.1016/j.ctro.2024.100877. eCollection 2025 Jan. Clin Transl Radiat Oncol. 2024. PMID: 39529652 Free PMC article.
Impact of underlying liver disease on unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
Wu YL, Cappuyns S, Loh A, Sun S, Lewis S, Sung MW, Schwartz M, Llovet JM, Cohen DJ. Wu YL, et al. BJC Rep. 2024 Jan 29;2(1):8. doi: 10.1038/s44276-024-00038-w. BJC Rep. 2024. PMID: 39516245 Free PMC article.
Implementing palliative care in hepatocellular carcinoma ambulatory clinics-study protocol for Accelerated translational research in PRImary liver CAncer (APRICA) randomised controlled palliative care trial.
Gofton C, Di Bartolomeo A, Boutros R, Zurynski YA, Stafford-Bell F, Caldwell K, McCaughan G, Zekry A, Strasser SI, Levy M, Sheehan C, Goodall S, Davis JM, Sheahan L, Liu K, Greenaway S, Davison S, Du Huynh T, Quadri Z, Agar M, George J. Gofton C, et al. Trials. 2024 Nov 7;25(1):743. doi: 10.1186/s13063-024-08603-x. Trials. 2024. PMID: 39506822 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

AASLD guidelines for the treatment of hepatocellular carcinoma

Affiliations

AASLD guidelines for the treatment of hepatocellular carcinoma

Authors

Affiliations

Similar articles

Cited by

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Similar articles

Cited by

Publication types

MeSH terms

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical